IN2014KN02993A - - Google Patents

Info

Publication number
IN2014KN02993A
IN2014KN02993A IN2993KON2014A IN2014KN02993A IN 2014KN02993 A IN2014KN02993 A IN 2014KN02993A IN 2993KON2014 A IN2993KON2014 A IN 2993KON2014A IN 2014KN02993 A IN2014KN02993 A IN 2014KN02993A
Authority
IN
India
Prior art keywords
compounds
modulators
making
methods
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Philip Stewart Turnbull
Rodolfo Cadilla
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014KN02993(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of IN2014KN02993A publication Critical patent/IN2014KN02993A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
IN2993KON2014 2012-07-17 2013-07-15 IN2014KN02993A (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672455P 2012-07-17 2012-07-17
US201361748874P 2013-01-04 2013-01-04
PCT/IB2013/001530 WO2014013309A1 (en) 2012-07-17 2013-07-15 Indolecarbonitriles as selective androgen receptor modulators

Publications (1)

Publication Number Publication Date
IN2014KN02993A true IN2014KN02993A (cs) 2015-05-08

Family

ID=49117887

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2993KON2014 IN2014KN02993A (cs) 2012-07-17 2013-07-15

Country Status (39)

Country Link
US (5) US8957104B2 (cs)
EP (1) EP2875013B1 (cs)
JP (1) JP6106746B2 (cs)
KR (1) KR102127939B1 (cs)
CN (1) CN104619693B (cs)
AR (1) AR091770A1 (cs)
AU (1) AU2013291721B2 (cs)
BR (1) BR112015000940B1 (cs)
CA (1) CA2879104C (cs)
CL (1) CL2015000119A1 (cs)
CO (1) CO7240378A2 (cs)
CR (1) CR20150008A (cs)
CY (1) CY1120064T1 (cs)
DK (1) DK2875013T3 (cs)
DO (1) DOP2015000004A (cs)
EA (1) EA026371B8 (cs)
ES (1) ES2657912T3 (cs)
HR (1) HRP20180061T1 (cs)
HU (1) HUE036238T2 (cs)
IL (1) IL236448A (cs)
IN (1) IN2014KN02993A (cs)
JO (1) JO3384B1 (cs)
LT (1) LT2875013T (cs)
ME (1) ME02996B (cs)
MX (1) MX349943B (cs)
MY (2) MY198512A (cs)
NZ (1) NZ703129A (cs)
PE (1) PE20150371A1 (cs)
PH (1) PH12015500104B1 (cs)
PL (1) PL2875013T3 (cs)
PT (1) PT2875013T (cs)
RS (1) RS56810B1 (cs)
SG (1) SG11201408493WA (cs)
SI (1) SI2875013T1 (cs)
SM (1) SMT201800115T1 (cs)
TW (1) TWI574946B (cs)
UY (1) UY34911A (cs)
WO (1) WO2014013309A1 (cs)
ZA (1) ZA201500096B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155099B2 (en) 2009-09-21 2018-12-18 Cook Regentec Llc Method for infusing stem cells
WO2014013309A1 (en) * 2012-07-17 2014-01-23 Glaxosmithkline Intellectual Property (No.2) Limited Indolecarbonitriles as selective androgen receptor modulators
EP3097077A1 (en) * 2014-01-21 2016-11-30 Glaxosmithkline Intellectual Property (No. 2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile
CN106999453A (zh) * 2014-10-16 2017-08-01 Gtx公司 使用sarm治疗泌尿病症的方法
CN105130872B (zh) * 2015-08-25 2018-01-30 江西师范大学 一种3位三氟甲基取代吲哚的制备方法
CN110437125B (zh) * 2019-09-06 2021-03-12 苏州旺山旺水生物医药有限公司 一种Tezacaftor中间体II的制备方法
US20220306609A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
CN115010574B (zh) * 2022-06-06 2024-01-05 爱斯特（成都）生物制药股份有限公司 1-溴-2-氯-4-氟-2碘苯的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200000486A (et) 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal
ATE265458T1 (de) * 1998-06-19 2004-05-15 Pfizer Prod Inc Pyrrolo(2,3-d)pyrimidin-verbindungen
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
AU2003245880A1 (en) 2002-05-24 2003-12-12 Bayer Cropscience Ag Process for the preparation of thioalkylamine derivatives
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
CN1960973A (zh) * 2004-03-30 2007-05-09 惠氏公司 作为去甲肾上腺素(ne)与血清素(5－h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1－(1h－吲哚－1－基)－3－(4－甲基哌嗪－1－基)－1－苯基丙烷－2－醇衍生物和相关化合物
AU2005243240B2 (en) 2004-05-03 2012-03-15 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (SARMS)
EP1771413B1 (en) 2004-05-03 2011-09-21 Janssen Pharmaceutica NV Benzofuran derivatives as selective androgen receptor modulators (sarms)
AU2005243238B2 (en) 2004-05-03 2011-11-10 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (SARMS)
MXPA06014018A (es) * 2004-06-01 2007-02-08 Hoffmann La Roche 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas.
US8232394B2 (en) * 2005-07-29 2012-07-31 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AU2007227681A1 (en) * 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
CN101426778A (zh) * 2006-03-15 2009-05-06 惠氏公司 作为组胺-3拮抗剂的n-经取代-氮杂环基胺
ES2452343T3 (es) 2006-09-29 2014-04-01 Glaxosmithkline Llc Compuestos de indol sustituidos
WO2010020905A1 (en) * 2008-08-20 2010-02-25 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
WO2010118287A1 (en) * 2009-04-10 2010-10-14 Radius Health, Inc. Selective androgen receptor modulators
PH12012500583A1 (en) * 2009-10-15 2012-10-22 Pfizer Pyrrolo[2,3-d] pyrimidine compounds
CA2782720A1 (en) * 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
CA2804161A1 (en) 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
RU2598842C2 (ru) * 2011-01-20 2016-09-27 Мерк Шарп Энд Домэ Корп. Антагонисты рецептора минералокортикоидов
CA2857977C (en) * 2011-12-21 2020-10-20 Jiangsu Hengrui Medicine Co., Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method thereof, and medicinal uses thereof
WO2014013309A1 (en) 2012-07-17 2014-01-23 Glaxosmithkline Intellectual Property (No.2) Limited Indolecarbonitriles as selective androgen receptor modulators
EP3097077A1 (en) * 2014-01-21 2016-11-30 Glaxosmithkline Intellectual Property (No. 2) Limited Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile

Also Published As

Publication number Publication date
US8957104B2 (en) 2015-02-17
US20200270210A1 (en) 2020-08-27
US10196353B2 (en) 2019-02-05
JP2015522603A (ja) 2015-08-06
US20170073309A1 (en) 2017-03-16
CA2879104C (en) 2020-08-25
WO2014013309A1 (en) 2014-01-23
EP2875013B1 (en) 2017-11-29
AU2013291721B2 (en) 2016-02-25
CY1120064T1 (el) 2018-12-12
US20190127326A1 (en) 2019-05-02
CO7240378A2 (es) 2015-04-17
SG11201408493WA (en) 2015-02-27
CR20150008A (es) 2015-03-09
CN104619693B (zh) 2019-08-13
SI2875013T1 (en) 2018-03-30
PE20150371A1 (es) 2015-03-27
BR112015000940B1 (pt) 2022-05-17
PL2875013T3 (pl) 2018-06-29
US11299457B2 (en) 2022-04-12
JP6106746B2 (ja) 2017-04-05
EP2875013A1 (en) 2015-05-27
HUE036238T2 (hu) 2018-06-28
ES2657912T3 (es) 2018-03-07
DK2875013T3 (en) 2018-01-22
PH12015500104A1 (en) 2015-03-02
HK1208867A1 (en) 2016-03-18
EA026371B1 (ru) 2017-03-31
ZA201500096B (en) 2017-07-26
SMT201800115T1 (it) 2018-03-08
RS56810B1 (sr) 2018-04-30
BR112015000940A2 (pt) 2017-06-27
AR091770A1 (es) 2015-02-25
IL236448A0 (en) 2015-02-26
US10710963B2 (en) 2020-07-14
US9533948B2 (en) 2017-01-03
MX349943B (es) 2017-08-21
NZ703129A (en) 2017-06-30
TW201416349A (zh) 2014-05-01
ME02996B (me) 2018-10-20
UY34911A (es) 2014-02-28
CL2015000119A1 (es) 2015-04-24
MY173845A (en) 2020-02-24
CA2879104A1 (en) 2014-01-23
MX2015000825A (es) 2015-07-17
EA026371B8 (ru) 2017-06-30
DOP2015000004A (es) 2015-03-15
AU2013291721A1 (en) 2015-02-26
PT2875013T (pt) 2018-02-28
CN104619693A (zh) 2015-05-13
MY198512A (en) 2023-09-01
IL236448A (en) 2016-10-31
PH12015500104B1 (en) 2015-03-02
EA201492237A1 (ru) 2015-06-30
KR20150032333A (ko) 2015-03-25
US20150080449A1 (en) 2015-03-19
LT2875013T (lt) 2018-02-26
TWI574946B (zh) 2017-03-21
HRP20180061T1 (hr) 2018-02-23
KR102127939B1 (ko) 2020-06-29
US20140024694A1 (en) 2014-01-23
JO3384B1 (ar) 2019-03-13

Similar Documents

Publication Publication Date Title
IL273567A (en) Derivatives of ((3a,5p,7a – 3, 7-deoxy-23-amino-24- norchaloane as modulators of FXR/TGR5
PH12018500718A1 (en) Compounds useful as modulators of trpm8
PH12016500968B1 (en) Octahydro fused azadecalin glucocorticoid receptor modulators
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MY172739A (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
GB201017345D0 (en) Receptor antagonists
MX2021009309A (es) Modulacion de la actividad del complemento.
PH12015500104A1 (en) Chemical compounds
IN2014DN05885A (cs)
IN2015DN00127A (cs)
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
JO3755B1 (ar) تركيبات تستوستيرون
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
TN2014000136A1 (en) Selective androgen receptor modulators
EP4487913A3 (en) Opioid receptor modulators
IN2013MU00848A (cs)
IN2015DN01688A (cs)
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
IN2014DN09450A (cs)
EP2994542A4 (en) Compositions for ovarian cancer assessment having improved specificity
IN2013MU01113A (cs)
IN2014DN10209A (cs)
HK40102817A (en) Compositions for ovarian cancer assessment having improved specificity